Journal of Adolescent Health
Volume 45, Issue 5 , Pages 438-444 , November 2009

Availability of Human Papillomavirus Vaccine at Medical Practices in an Area with Elevated Rates of Cervical Cancer

  • Sami L. Gottlieb, M.D., M.S.P.H.

      Affiliations

    • Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
    • Corresponding Author InformationAddress correspondence to: Sami L. Gottlieb, M.D., M.S.P.H., Division of STD Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS E-02, Atlanta, GA 30333.
    • ,
  • Noel T. Brewer, Ph.D.

      Affiliations

    • UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
    • ,
  • Jennifer S. Smith, Ph.D.

      Affiliations

    • UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
    • ,
  • Katie M. Keating, M.P.H.

      Affiliations

    • UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina
    • ,
  • Lauri E. Markowitz, M.D.

      Affiliations

    • Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

Received 24 November 2008 ,Accepted 28 May 2009.

References 

  1. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943
  2. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459–1466
  3. Press Release: CDC's Advisory Committee Recommends Human Papillomavirus Vaccination, June 29, 2006. Available at: http://www.cdc.gov/od/oc/media/pressrel/r060629.htm. Accessed March 3, 2009.
  4. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24
  5. National Cancer Institute. SEER Stat Fact Sheets—Cancer of the Cervix Uteri. Available at: http://seer.cancer.gov/statfacts/html/cervix.html. Accessed March 3, 2009.
  6. Gottlieb SL, Brewer NT, Sternberg MR, et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health. 2009;45:430–437
  7. National Cancer Institute. SEER Cancer Statistics—Fast Stats. Available at: http://seer.cancer.gov/faststats/selections.php#Output. Accessed March 3, 2009.
  8. Santoli JM, Rodewald LE, Maes EF, et al. Vaccines for Children program, United States, 1997. Pediatrics. 1999;104(2):e15
  9. Schaffer SJ, Szilagyi PG, Shone LP, et al. Physician perspectives regarding pneumococcal conjugate vaccine. Pediatrics. 2002;110(6):e68
  10. Freed GL, Freeman VA, Clark SJ, et al. Pediatrician and family physician agreement with and adoption of universal hepatitis B immunization. J Fam Pract. 1996;42(6):587–592
  11. Davis MM, Ndiaye SM, Freed GL, Clark SJ. One-year uptake of pneumococcal conjugate vaccine: a national survey of family physicians and pediatricians. J Am Board Fam Pract. 2003;16(5):363–371
  12. Committee on Adolescent Health Care. ACOG Working Group on Immunization. ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol. 2006;108(3, Pt 1):699–705
  13. Rand CM, Shone LP, Albertin C, et al. National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med. 2007;161(3):252–259
  14. Davis MM, Ndiaye SM, Freed GL, et al. Influence of insurance status and vaccine cost on physicians' administration of pneumococcal conjugate vaccine. Pediatrics. 2003;112(3, Pt 1):521–526
  15. Kempe A, Daley MF, Parashar UD, et al. Will pediatricians adopt the new rotavirus vaccine?. Pediatrics. 2007;119(1):1–10
  16. Lee GM, Santoli JM, Hannan C, et al. Gaps in vaccine financing for underinsured children in the United States. JAMA. 2007;298(6):638–643
  17. Keating KM, Brewer NT, Gottlieb SL, et al. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health. 2008;43(4 Suppl):S61–S67
  18. McInerny TK, Cull WL, Yudkowsky BK. Physician reimbursement levels and adherence to American Academy of Pediatrics well-visit and immunization recommendations. Pediatrics. 2005;115(4):833–838
  19. Dempsey AF, Davis MM. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care. 2006;12(17 Suppl):S484–S491
  20. Glazner JE, Beatty BL, Pearson KA, Berman S. The cost of giving childhood vaccinations: differences among provider types. Pediatrics. 2004;113(6):1582–1587
  21. Freed GL, Cowan AE, Gregory S, Clark SJ. Variation in provider vaccine purchase prices and payer reimbursement. Pediatrics. 2008;122(6):1325–1331
  22. Jacobson VJ, Szilagyi P. Patient reminder and patient recall systems to improve immunization rates. Cochrane Database Syst Rev. 2005;(3):CD003941
  23. Centers for Disease Control and Prevention. Immunization Strategies for Healthcare Practices and Providers. Available at: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/strat-508.pdf. Accessed July 7, 2009.
  24. Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult immunization and cancer screening services: a meta-analysis. Ann Intern Med. 2002;136(9):641–651
  25. Daley MF, Liddon N, Crane LA, et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics. 2006;118(6):2280–2289
  26. Middleman AB. Adolescent immunizations: policies to provide a shot in the arm for adolescents. J Adolesc Health. 2007;41(2):109–118

PII: S1054-139X(09)00212-2

doi: 10.1016/j.jadohealth.2009.05.013

Journal of Adolescent Health
Volume 45, Issue 5 , Pages 438-444 , November 2009

Article Tools

* Image Usage & Resolution